NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Up to $16 Million Senior Secured Debt Financing from Anson Funds
This financing is expected to support 2024 filing of New Drug Applications forNRX-100 (ketamine) and NRX-101 and to support launch...
Clinical Trial
Life Sciences Community Advances Toward Next Phase of Innovation at Veeva R&D and Quality Summit
AbbVie, Astellas, Eikon, Merck, Moderna, Roche, and more share new ideas to advance drug development PLEASANTON, Calif., Aug. 13, 2024...
Acclinate Ranks No. 539 on the 2024 Inc. 5000 List
NEW YORK, Aug. 13, 2024 /PRNewswire/ -- Inc. magazine revealed today that Acclinate has ranked No. 539 on its 2024...
Leapcure Acquires Honeybee Trials: Expanding Patient Engagement and Research Site Solutions for Clinical Trials
Leapcure enhances clinical trials and affordable patient recruitment with strategic acquisition of Honeybee Trials.REDWOOD CITY, CA / ACCESSWIRE / August...
U.S. News & World Report Ranks John Theurer Cancer Center as the #1 Cancer Program in NJ and the Only Top 50 Cancer Program in the State
Regional Cancer Care Associates is pleased to announce the recognition of John Theurer Cancer Center as the #1 Cancer Program...
Phase 1b/2 “RAINIER” Frontline Acute Myeloid Leukemia (AML) Trial Initiated
Aptevo's lead candidate APVO436 (mipletamig) to be evaluated in combination with standard of care venetoclax and azacitidineCompany anticipates new data...
Jaguar Health Reports Second Quarter 2024 Financial Results
The combined net Q2 2024 revenue of approximately $2.72 million for prescription and non-prescription products increased approximately 16% versus net...
NeurAxis Announces BCBS of Vermont Medical Policy Coverage for PENFS, effective October 1st 2024
CARMEL, Ind., Aug. 13, 2024 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology...
Microbot Medical Receives Quality Certification to Support Future Regulatory Submissions and Commercialization
The ISO 13485 certification is a validation of the Company’s robust quality systemBRAINTREE, Mass., Aug. 13, 2024 (GLOBE NEWSWIRE) --...
COSCIENS Biopharma Inc. Reports Second Quarter 2024 Financial Results
Data from pivotal DETECT-Trial evaluating macimorelin for the diagnosis of childhood-onset growth hormone...
Palisade Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
– Continued progress toward commencement of Phase 1 human clinical study of lead product candidate, PALI-2108, for the treatment of...
Mereo BioPharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Phase 3 Orbit and Cosmic studies of setrusumab in OI, conducted by our partner Ultragenyx, fully enrolled New long-term Phase...
Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
Published data show that responses from 1-month and 24-hour recall patient reported outcome (PRO) instruments were similar and support that...
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
NAVIGATE trial on track for interim top-line analysis in December 2024 NORCROSS, Ga., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Galectin...
Replimune Announces First Patient Dosed in IGNYTE-3 Clinical Trial in Advanced Melanoma
Confirmatory Phase 3 Trial to assess efficacy and safety of the investigational oncolytic immunotherapy, RP1 (vusolimogene oderparepvec) in combination with...
Artelo Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update
SOLANA BEACH, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on...
Autonomix Medical, Inc. Reports First Quarter Fiscal Year 2025 Financial Results and Reiterates Near-Term Milestones
First-in-class catheter-based sensing and ablation technology that targets neural signals that indicate pain or disease and destroys them at the...
Ovid Therapeutics Reports Business Updates and Second Quarter 2024 Financial Results
Appointed Dr. Amanda Banks, a tenured physician and biotech leader, as Chief Development Officer to lead clinical strategy and executionExpanded...
Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial
43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial...
Teknova Introduces Proprietary Express-Tek℠ Production Service and Expanded Manufacturing Grade Options to Expedite Novel Therapy Development
Express-TekSM Production enables customers to have their products enter production in days instead of weeks, significantly shortening turnaround time New...